180 related articles for article (PubMed ID: 35137546)
21. Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome.
Iolascon A; Lo Cunsolo C; Giordani L; Cusano R; Mazzocco K; Boumgartner M; Ghisellini P; Faienza MF; Boni L; De Bernardi B; Conte M; Romeo G; Tonini GP
Cancer Lett; 1998 Aug; 130(1-2):83-92. PubMed ID: 9751260
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of
Ren J; Fu Z; Zhao Y
Front Oncol; 2023; 13():1099290. PubMed ID: 37035169
[TBL] [Abstract][Full Text] [Related]
23. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
[TBL] [Abstract][Full Text] [Related]
25. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Pinto N; Naranjo A; Ding X; Zhang FF; Hibbitts E; Kennedy R; Tibbetts R; Wong-Michalak S; Craig DW; Manojlovic Z; Hogarty MD; Kreissman S; Bagatell R; Irwin MS; Park JR; Asgharzadeh S
Clin Cancer Res; 2023 Apr; 29(8):1546-1556. PubMed ID: 36749880
[TBL] [Abstract][Full Text] [Related]
26. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification.
Huang C; Jiang S; Yang J; Liao X; Li Y; Li S
Medicine (Baltimore); 2020 Jun; 99(25):e20853. PubMed ID: 32569234
[TBL] [Abstract][Full Text] [Related]
28. Locoregional MYCN-amplified neuroblastoma.
Morales La Madrid A; Volchenboum S; Gastier-Foster JM; Pyatt R; Liu D; Pytel P; Lavarino C; Rodriguez E; Cohn SL
Pediatr Blood Cancer; 2012 Oct; 59(4):736-8. PubMed ID: 22213566
[TBL] [Abstract][Full Text] [Related]
29. Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.
Coco S; Defferrari R; Scaruffi P; Cavazzana A; Di Cristofano C; Longo L; Mazzocco K; Perri P; Gambini C; Moretti S; Bonassi S; Tonini GP
J Pathol; 2005 Nov; 207(3):346-57. PubMed ID: 16178058
[TBL] [Abstract][Full Text] [Related]
30. Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma.
Mora J; Gerald WL; Cheung NK
Cancer Lett; 2003 Jul; 197(1-2):119-24. PubMed ID: 12880970
[TBL] [Abstract][Full Text] [Related]
31. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
[TBL] [Abstract][Full Text] [Related]
32. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Kao PC; Naranjo A; Kamijo T; Ramanujachar R; London WB; DuBois SG
Pediatr Blood Cancer; 2023 Feb; 70(2):e30054. PubMed ID: 36316811
[TBL] [Abstract][Full Text] [Related]
33. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
Pinto N; Naranjo A; Hibbitts E; Kreissman SG; Granger MM; Irwin MS; Bagatell R; London WB; Greengard EG; Park JR; DuBois SG
Eur J Cancer; 2019 May; 112():66-79. PubMed ID: 30947024
[TBL] [Abstract][Full Text] [Related]
34. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
35. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
[TBL] [Abstract][Full Text] [Related]
36. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
[TBL] [Abstract][Full Text] [Related]
37. No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.
Hogarty MD; Winter CL; Liu X; Guo C; White PS; Look AT; Brodeur GM; Maris JM
Cancer Res; 2002 Nov; 62(22):6481-4. PubMed ID: 12438240
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
[TBL] [Abstract][Full Text] [Related]
39. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
[TBL] [Abstract][Full Text] [Related]
40. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project.
Moreno L; Guo D; Irwin MS; Berthold F; Hogarty M; Kamijo T; Morgenstern D; Pasqualini C; Ash S; Potschger U; Ladenstein R; Valteau-Couanet D; Cohn SL; Pearson ADJ; London WB
Pediatr Blood Cancer; 2021 Mar; 68(3):e28794. PubMed ID: 33205902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
